First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series

doi:10.5306/wjco.v12.i11.1037

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3878)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

247

WORD

108

HTML

1659

Figures (1-1)

471

Tables (1-3)

243

Sum=2728

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

347

Download

803

Sum=1150

Nov 24, 2021 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Nov 24, 2021; 12(11): 1037-1046
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1037

Table 1 Characteristics of patients, n (%)

Baseline characteristic	n = 48
Age, median (range)	70 (27-86)
Sex
Males	36 (75)
Females	12 (25)
Histology
Papillary	24 (50)
Chromophobe	9 (10.8)
Xp11 translocation	1 (2.1)
Unclassified	6 (12.5)
Mixed¹	8 (16.7)
Grade (Fuhrman/ISUP)
1-2	6 (12.5)
3	15 (31.3)
4	4 (8.3)
NA	23 (47.9)
Stage at diagnosis
I-III	33 (68.8)
IV	15 (31.3)
Previous nephrectomy
Yes	41 (85.4)
No	7 (14.6)
Metastasectomy
Yes	7 (14.6)
No	41 (85.4)
ECOG PS
0	37 (77.1)
1	11 (22.9)
IMDC score risk group
Good	19 (39.6)
Intermediate	25 (52.1)
Poor	2 (4.2)
NA	2 (4.2)
Starting dose of pazopanib
800 mg	31(64.6)
600 mg	10 (20.8)
400 mg	7 (14.6)

¹Four tumors had mixed histology (clear-cell/papillary) with papillary histology prevalence and four tumors had mixed histology (clear-cell/chromophobe) with chromophobe histology prevalence.

NA: Not assessed/available; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; ECOG PS: Eastern Cooperative Oncology Group Performance Status; ISUP: International Society of Urological Pathology.

Citation: Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, Petrelli F, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World J Clin Oncol 2021; 12(11): 1037-1046
URL: https://www.wjgnet.com/2218-4333/full/v12/i11/1037.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i11.1037